Prostate Clinic London

Can Prostate Cancer Upgrade While You Are on Active Surveillance?

If you have been told your prostate cancer has “upgraded” while you are on active surveillance, it is understandable to wonder whether this means the cancer has suddenly become more aggressive or that you now need treatment. An upgrade can reflect a real change, but it can also happen because a later biopsy finds higher-grade cancer that was missed earlier.

It does not automatically mean active surveillance must stop. Your doctor will review the biopsy alongside your MRI, PSA pattern, cancer volume, age, health and preferences before discussing what the change means for you.

What Does Prostate Cancer Upgrading Mean?

If you have prostate cancer, upgrading means a later biopsy has found a higher Grade Group than your original diagnosis. This could mean moving from Grade Group 1 to Grade Group 2, although the higher-grade cancer may have been present from the start but missed by the first biopsy.

If your cancer is upgraded, it does not automatically mean the cancer has become more aggressive. Your doctor will consider the new biopsy alongside your MRI, PSA and other results to understand whether this represents true progression or improved detection.

Understanding Grade Groups

Grade Groups from 1 to 5 describe how prostate cancer cells look under a microscope and help indicate how the cancer may behave. Grade Group 1 usually means Gleason 3+3, Grade Group 2 means 3+4, and Grade Group 3 means 4+3, while Groups 4 and 5 contain higher-grade patterns.

If your Grade Group changes, it is not the only factor your doctor will consider. The amount and pattern of cancer, PSA, MRI findings and cancer stage all help determine what the change means for your care.

Why Can the First Biopsy Underestimate the Grade?

If you have a prostate biopsy, only selected areas of your prostate are sampled, so a higher-grade cancer elsewhere can sometimes be missed. This can happen because different areas of your prostate may contain different cancer grades.

If a later MRI-targeted or systematic biopsy finds Gleason pattern 4 that was not sampled initially, your Grade Group may be upgraded. This does not necessarily mean the cancer changed; the later biopsy may simply provide a more complete picture.

Research Insight

Research shows that different biopsy methods can identify different areas of prostate cancer. In one active surveillance study, combining MRI-targeted and systematic biopsy detected more grade progression than either method alone.

This means that an upgrade on a later biopsy may sometimes reflect better detection of higher-grade cancer that was already present rather than a recent change in the cancer itself.

Can Prostate Cancer Genuinely Become Higher Grade?

Doctor talking with an older man in a clinic

Yes, if you are on active surveillance, your cancer can become higher grade over time. However, an upgrade may also mean a higher-grade area was missed during your first biopsy.

If your cancer is upgraded, your doctor will look at your full results rather than assuming it has progressed. Active surveillance is designed to detect these changes early and help you decide when treatment may be needed.

Why Active Surveillance Includes Regular Monitoring

Active surveillance is not the same as leaving prostate cancer untreated. Regular PSA tests, MRI scans and, when needed, repeat biopsies help your doctor check that monitoring is still a safe option for you.

If your results change, your doctor can investigate further and discuss treatment when needed. PSA, MRI and biopsy each provide different information, helping your team understand whether your cancer is changing.

TestWhat it helps assessImportant limitation
PSAChanges in PSA level or patternCannot confirm upgrading
PSA densityPSA in relation to prostate sizeMust be interpreted with other findings
MRIChanges in known or new suspicious areasStable MRI cannot completely exclude upgrading
BiopsyGrade Group and amount of cancerSampling may miss some areas
DREClinical changes in the prostateCannot determine Grade Group

How PSA Changes Are Used During Surveillance

A rising PSA can be worrying, but it does not automatically mean your cancer has upgraded. Your doctor will look at the pattern over time, repeat the test if needed, and consider your prostate size and PSA density.

If your PSA continues to change or other results are concerning, you may need an MRI or biopsy. PSA can signal that further assessment is needed, but only tissue examination can confirm whether your Grade Group has changed.

The Role of MRI in Detecting Possible Changes

If you are on active surveillance, MRI can help your doctor check whether known areas of cancer have changed or whether a new suspicious area has appeared. A concerning MRI may lead to a targeted biopsy to check your cancer more closely.

A stable MRI is reassuring, but it cannot completely rule out a Grade Group change. Your doctor will compare scans over time with your PSA and biopsy results. NICE recommends multiparametric MRI for people on active surveillance who have not previously had one. If that MRI does not agree with the biopsy findings, a new MRI-influenced biopsy should be offered.

Evidence Note

A systematic review involving 15 studies and 2,240 men found that serial MRI alone was not accurate enough to reliably confirm or exclude prostate cancer progression during active surveillance.

This means a stable MRI is reassuring but cannot completely rule out an upgrade. Your specialist will interpret MRI findings alongside your PSA, biopsy results and wider clinical picture.

Why You May Need Another Biopsy

If your doctor needs to check whether your cancer has changed grade, you may need another biopsy. Fresh tissue samples allow a pathologist to examine your cancer under a microscope and confirm its Grade Group.

If your MRI shows a suspicious area, your biopsy may include MRI-targeted samples and systematic samples from other parts of the prostate. The timing depends on your PSA, MRI, previous biopsy and overall risk, and an upgrade needs to be considered alongside how much higher-grade cancer is present.

What Happens If Grade Group 1 Becomes Grade Group 2?

Doctor talking with an older man in a clinic

Moving from Grade Group 1 to Grade Group 2 means Gleason pattern 4 has been found alongside pattern 3. This is an important change, but how much pattern 4 is present can affect what it means for your risk.

If you have Grade Group 2 cancer, your doctor will also consider your PSA, MRI, cancer stage and overall cancer volume. An upgrade may lead to a detailed review rather than automatically meaning you need treatment.

UK Guidance Note

In the UK, your Grade Group is considered alongside your PSA and tumour stage when determining your Cambridge Prognostic Group (CPG). NICE recommends active surveillance for CPG 1 and includes active surveillance as one of the management options for suitable people with CPG 2 localised prostate cancer.

Therefore, an upgrade to Grade Group 2 does not automatically mean active surveillance must stop. Your overall risk, amount of higher-grade cancer, MRI findings, PSA, health and preferences should all be considered.

Does Every Upgrade Mean Active Surveillance Must Stop?

No. If your cancer is upgraded, active surveillance does not automatically have to stop. Your doctor will consider the new Grade Group, amount of higher-grade cancer, PSA, MRI and overall risk before deciding whether surveillance remains suitable for you.

If your upgrade shows more extensive or higher-risk disease, treatment may be discussed. It is more useful to ask how much your overall risk has changed rather than focusing only on the word ‘upgrade’.

The Amount of Higher-Grade Cancer Matters

How much higher-grade cancer is found also matters. A small focus may have different implications from higher-grade cancer found across several biopsy samples.

If you are reviewing an upgrade, your doctor will consider your pathology, MRI and cancer location together. Ask how much higher-grade cancer was found and what this means for your overall risk.

Clinical Note

Two men can both move from Grade Group 1 to Grade Group 2 but still have different levels of risk. Your specialist will look at how much Gleason pattern 4 was found, how many biopsy samples contain cancer, your PSA, MRI findings and clinical stage.

A small amount of higher-grade cancer may therefore be assessed differently from more extensive disease. Ask your specialist exactly how much cancer was found and how the upgrade changes your overall risk.

When Is Treatment More Likely to Be Recommended?

If your surveillance shows higher-risk cancer, treatment may become more likely. Your doctor will consider changes in Grade Group, cancer volume, MRI, stage and PSA rather than relying on one result alone.

If treatment is recommended, it does not mean you made the wrong choice by choosing active surveillance. Surveillance helped you avoid treatment while your cancer remained suitable and allowed your team to identify when that balance changed.

What Changes Can Lead to Treatment?

Active surveillance may continue while your cancer remains suitable for monitoring, but some changes can lead to treatment.

  • Biopsy upgrade: A higher Grade Group or more higher-grade cancer is found.
  • MRI changes: New or more suspicious areas appear.
  • PSA pattern: A concerning PSA trend may lead to further assessment.
  • Overall risk: Stage, cancer volume and PSA density may change your risk.
  • Your preference: You may choose treatment if you no longer feel comfortable with surveillance.

Starting treatment later does not mean surveillance has failed. It means treatment is being considered when your risk or circumstances have changed.

Could a Pathology Review Change the Grade?

Doctor reviewing tissue images on a monitor

Where there is uncertainty about the biopsy grade, particularly if a small amount of pattern 4 could affect your treatment options, your case may sometimes be reviewed by a specialist uropathologist.

If your grade is reviewed, it does not necessarily mean the original report was wrong. Having your pathology, MRI and clinical findings considered together can provide a clearer picture before you make treatment decisions.

How Your Age and General Health Affect the Decision

If your cancer is upgraded, your age and general health can affect whether continuing surveillance or treatment is considered appropriate. Your doctors will also consider your overall health, life expectancy, cancer characteristics and personal priorities.

If you are discussing an upgrade, the same biopsy result may lead to different recommendations for different men. The decision should focus on whether treatment is likely to provide enough benefit for you to justify its possible effects.

What Treatment Options May Be Discussed After an Upgrade?

If your cancer is upgraded and surveillance is no longer considered suitable, your doctor may discuss surgery or radiotherapy for localised prostate cancer. Your options will depend on your cancer, health and preferences, including specialist guidance about prostate cancer surgery in London.

If treatment is being considered, ask your specialist how quickly a decision is needed. In many cases, there is time to understand the benefits, risks and possible effects on your quality of life before choosing between the options.

Has Active Surveillance Made Treatment Less Effective?

If your cancer has upgraded, you may worry that active surveillance allowed it to become harder to treat. An upgrade does not automatically mean surveillance was a mistake, as regular monitoring is designed to detect meaningful changes while treatment may still be possible.

If you are concerned about your treatment options, ask your specialist whether your stage or available treatments have changed. Your PSA, MRI and biopsy results can provide a clearer picture than assuming an upgrade means an opportunity was missed.

Coping With the Anxiety of an Upgrade

If you are told your cancer has upgraded, you may understandably feel more anxious about continued surveillance. Hearing ‘higher grade’ does not automatically mean treatment is immediately needed, so ask your doctor what has actually changed.

If you are reviewing your results, ask your specialist to compare your new biopsy with your previous MRI, PSA and biopsy findings. Involving someone you trust in appointments can also help, and you should tell your team if ongoing surveillance is becoming difficult.

Questions to Discuss With Your Specialist

Doctor talking with an older man in a clinic

If your prostate cancer has upgraded, use your next appointment to understand what has changed rather than focusing only on your new Grade Group. Ask how much higher-grade cancer was found, whether it may have been missed before, and how your MRI and PSA compare with earlier results.

If your risk has changed, ask whether active surveillance is still suitable and whether your case has been reviewed by a multidisciplinary team. If treatment is recommended, ask why it is needed now, what your options are and whether you have time to consider them carefully.

Myth vs Fact

MythFact
An upgrade means active surveillance has failed.An upgrade means your cancer needs reassessment and may reflect progression or improved detection.
Grade Group 2 always requires treatment.Some appropriately selected men with CPG 2 disease may remain suitable for active surveillance.
A rising PSA proves the cancer has upgraded.PSA may indicate the need for further assessment, but biopsy determines Grade Group.
A stable MRI rules out an upgrade.MRI can miss some higher-grade disease, so other findings still matter.
An upgrade means the cancer has spread.Upgrading refers to grade; cancer spread relates to stage.

Key Takeaways

  • Upgrading means a later biopsy has identified a higher Grade Group.
  • It may represent genuine progression or cancer that was missed on an earlier biopsy.
  • PSA and MRI can indicate that further investigation is needed, but biopsy confirms Grade Group.
  • Grade Group 2 does not automatically mean active surveillance must stop.
  • The amount of higher-grade cancer, PSA, MRI, stage and your overall health all influence the next step.
  • Active surveillance is designed to identify important changes so treatment can be considered when it becomes appropriate.

Frequently Asked Questions

1. What Does Prostate Cancer Upgrading Mean During Active Surveillance?
Upgrading means a later biopsy has found a higher Grade Group than your original diagnosis. This may reflect cancer that was missed initially rather than cancer that has necessarily become more aggressive.

2. Can Prostate Cancer Really Become Higher Grade During Active Surveillance?
Yes, prostate cancer can become higher grade over time, but an upgrade can also happen because a later biopsy detects an area that was present but missed initially. Your doctor will consider your PSA, MRI and biopsy findings together to understand what has changed.

3. Does a Rising PSA Mean Your Prostate Cancer Has Upgraded?
No. A rising PSA does not automatically mean your cancer has upgraded. Your doctor may repeat the PSA test and consider your PSA pattern, prostate size and PSA density before deciding whether you need an MRI or biopsy.

4. Why Might You Need Another Biopsy During Active Surveillance?
You may need another biopsy to check whether your cancer has changed or whether a higher-grade area was missed previously. Fresh tissue samples allow a pathologist to reassess your Grade Group and the amount of cancer present.

5. What Happens If Your Cancer Upgrades From Grade Group 1 to 2?
This means Gleason pattern 4 has been found alongside pattern 3. The amount of pattern 4, cancer volume, PSA, MRI findings and stage can all affect whether active surveillance remains suitable for you.

6. Does Every Prostate Cancer Upgrade Mean You Need Treatment?
No. An upgrade does not automatically mean you need surgery or radiotherapy. Your doctor will consider the new Grade Group, amount of higher-grade cancer, PSA, MRI and overall risk before deciding whether surveillance can continue.

7. What If Your MRI and Biopsy Results Do Not Agree?
MRI and biopsy provide different information, so your results may not always match. If your biopsy shows an upgrade but your MRI remains stable, or your MRI becomes more suspicious without an upgrade, your specialist may review both results together or arrange further assessment.

8. Can a Pathology Review Change Your Prostate Cancer Grade?
Yes, a specialist pathology review may sometimes change how your biopsy is interpreted, particularly when a higher-grade area is small or difficult to assess. This can provide greater clarity for you before treatment decisions are made.

9. When Is Treatment More Likely After an Upgrade?
Treatment may be discussed if your surveillance shows higher-risk or more extensive cancer. Your doctor will consider your Grade Group, cancer volume, MRI, stage and PSA, as well as your age, general health and personal priorities.

10. Does an Upgrade Mean Active Surveillance Was the Wrong Choice?
Not necessarily. Active surveillance is designed to monitor your cancer and identify meaningful changes while treatment may still be possible. If your cancer upgrades, your specialist can reassess whether continued surveillance or treatment is now more appropriate.

Final Thoughts: What Should You Know About Prostate Cancer Upgrading During Active Surveillance?

An upgrade during active surveillance means a later biopsy has found a higher Grade Group than your original diagnosis, although this may sometimes reflect a higher-grade area that was missed initially. An upgrade does not automatically mean you need treatment, as your doctor will also consider your MRI, PSA pattern, cancer volume, overall health and other risk factors.

If you are considering prostate cancer surgery in London, you can contact Prostate Clinic London to discuss your treatment options and arrange a consultation.

References:

  1. Inoue, L.Y.T., Trock, B.J., Partin, A.W., Carter, H.B. and Etzioni, R. (2014) ‘Modeling grade progression in an active surveillance study’, Statistics in Medicine, 33(6), pp. 930–939. Available at: https://pubmed.ncbi.nlm.nih.gov/24123208/
  2. National Institute for Health and Care Excellence (2021) Prostate cancer: diagnosis and management. NICE guideline NG131. Published 9 May 2019; last updated 15 December 2021. Available at: https://www.nice.org.uk/guidance/ng131
  3. Rajwa, P., Pradere, B., Quhal, F., Mori, K., Laukhtina, E., Huebner, N.A., D’Andrea, D., Krzywon, A., Shim, S.R., Baltzer, P.A., Renard-Penna, R., Leapman, M.S., Shariat, S.F. and Ploussard, G. (2021) ‘Reliability of serial prostate magnetic resonance imaging to detect prostate cancer progression during active surveillance: a systematic review and meta-analysis’, European Urology, 80(5), pp. 549–563. Available at: https://pubmed.ncbi.nlm.nih.gov/34020828/
  4. Schoots, I.G., Nieboer, D., Giganti, F., Moore, C.M., Bangma, C.H. and Roobol, M.J. (2018) ‘Is magnetic resonance imaging-targeted biopsy a useful addition to systematic confirmatory biopsy in men on active surveillance for low-risk prostate cancer? A systematic review and meta-analysis’, BJU International, 122(6), pp. 946–958. Available at: https://pubmed.ncbi.nlm.nih.gov/29679430/
  5. Willemse, P.P.M., Davis, N.F., Grivas, N., Zattoni, F., Lardas, M., Briers, E., Cumberbatch, M.G., De Santis, M., Dell’Oglio, P., Donaldson, J.F., Fossati, N., Gandaglia, G., Gillessen, S., Grummet, J.P., Henry, A.M., Liew, M., MacLennan, S., Mason, M.D., Moris, L. et al. (2022) ‘Systematic review of active surveillance for clinically localised prostate cancer to develop recommendations regarding inclusion of intermediate-risk disease, biopsy characteristics at inclusion and monitoring, and surveillance repeat biopsy strategy’, European Urology, 81(4), pp. 337–346. Available at: https://pubmed.ncbi.nlm.nih.gov/34980492/
  6. Yerram, N.K., Long, L., O’Connor, L.P., Wang, A.Z., Ahdoot, M., Lebastchi, A.H., Gurram, S., Zeng, J., Chalfin, H., Harmon, S.A., Mehralivand, S., Merino, M.J., Parnes, H.L., Choyke, P.L., Shih, J., Wood, B.J., Turkbey, B. and Pinto, P.A. (2021) ‘Magnetic resonance imaging-targeted and systematic biopsy for detection of grade progression in patients on active surveillance for prostate cancer’, The Journal of Urology, 205(5), pp. 1352–1360. Available at: https://pubmed.ncbi.nlm.nih.gov/33356479/